Here are the 10-Q quarterly reports from Aimfinity Inv CP I Subunt (AIMTF) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AIMTF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIMTF filings page.
Aimfinity Investment Corp. I, a SPAC, reported net income of $117,673 for the nine months ended September 30, 2025, driven by $630,505 of interest on cash and investments in its trust account, which more than offset $512,832 of formation and operating costs. The trust account balance fell to $14,294,569 from $36,940,228 at year-end 2024, mainly after redeeming 1,996,522 Class A shares for a total of $23,778,577.
Outside the trust, cash was only $3,517 with a working capital deficit of $2,785,815, and management concluded that these conditions, together with the limited time left to complete a merger, raise substantial doubt about the company’s ability to continue as a going concern. The SPAC continues to pursue a business combination with Docter Inc., has amended its charter multiple times to extend its deadline (with deposits totaling $1,808,413 into the trust for extensions), and has converted $1,500,000 of sponsor loans into 150,000 private units while restructuring deferred underwriting fees into a mix of cash and stock payable at closing.
Aimfinity Investment Corp. I filed its 10-Q showing modest non-operating profits and significant balance sheet changes typical of a SPAC nearing its deadline. For the six months ended June 30, 2025, the company reported net income of $75,425, driven by $484,941 of interest on trust assets and $409,516 of formation and operating costs. For Q2, net income was $10,494.
Trust assets were $13,981,534 as of June 30, 2025, after the redemption of 1,996,522 Class A shares for $23,778,577. 1,116,476 ordinary shares were classified as redeemable at $12.52 each. Working capital showed a deficit of $2,515,028, and management disclosed “substantial doubt” about continuing as a going concern absent a business combination by the extended deadline.
The company continues to pursue its merger with Docter Inc. It converted $1,500,000 of sponsor loans into 150,000 private units on April 8, 2025, and restructured deferred IPO underwriting fees on June 13, 2025 to $80,000 cash plus 132,875 PubCo shares for each underwriter at closing. Extensions funded through deposits push the combination window to October 28, 2025.